Headquartered in Bridgewater, New Jersey, Kashiv Pharma, LLC is an emerging pharmaceutical research and drug delivery company focused on developing innovative technologies, improved medicines, and life-cycle management products. Led by Dr. Navnit Shah, Kashiv is developing next generation drug delivery platforms and applying these proprietary technologies to create improved versions of known medicines with meaningful clinical differentiation and compelling value propositions for patients, physicians, and payers. It utilizes the FDA’s accelerated regulatory approval process to bring these improved drugs to market.

Tarsadia’s investor group made an initial investment in Kashiv in 2010. Today, Kashiv has over 100 employees, including over 40 Ph.D. scientists with extensive pre-formulation, analytical, formulation, drug development, regulatory approval, and commercialization experience from a variety of major research-based pharmaceutical, biotechnology, and drug delivery companies.